Immunomodulatory factors galectin-9 and interferon-gamma synergize to induce expression of rate-limiting enzymes of the Kynurenine pathway in the mouse hippocampus

Frontiers in Immunology

Volumn 7, Issue OCT, 2016, Pages

  Brooks, Alexandra K ^a   Lawson, Marcus A ^a   Rytych, Jennifer L ^a   Yu, Kevin C ^a   Janda, Tiffany M ^a   Steelman, Andrew J ^a   McCusker, Robert H ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Cytokines; Galectin 9; IDO1; IFN ; Kynurenine pathway; Neuroinflammation

Indexed keywords

ECALECTIN; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; KYNURENINE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HIPPOCAMPUS; IMMUNOMODULATION; MALE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 84997229080     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00422     Document Type: Article

References (63)

1. Raison CL, Miller AH. Is depression an inflammatory disorder? Curr Psychiatry Rep (2011) 13:467-75. doi:10.1007/s11920-011-0232-0.
2. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry (2002) 7:468-73. doi:10.1038/sj.mp.4000995.
3. Constant A, Castera L, Dantzer R, Couzigou P, De Ledinghen V, Demotes-Mainard J, et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry (2005) 66:1050-7. doi:10.4088/JCP.v66n0814.
4. Dantzer R, Kelley KW. Twenty years of research on cytokine induced sickness. Brain Behav Immunol (2007) 21:153-60. doi:10.1016/j.bbi.2006.09.006.
5. Dantzer R, O'Connor JC, Lawson MA, Kelley KW. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology (2011) 36:426-36. doi:10.1016/j.psyneuen.2010.09.012.
6. Gibney SM, McGuinness B, Prendergast C, Harkin A, Connor TJ. Poly I: C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain Behav Immun (2013) 28:170-81. doi:10.1016/j.bbi.2012.11.010.
7. Hoyo-Becerra C, Schlaak JF, Hermann DM. Insights from interferon-a-related depression for the pathogenesis of depression associated with inflammation. Brain Behav Immun (2014) 42:222-31. doi:10.1016/j.bbi.2014.06.200.
8. O'Connor JC, Lawson MA, André C, Briley EM, Szegedi SS, Lestage J, et al. Induction of IDO by Bacille Calmette-Guérin is responsible for development of murine depressive-like behavior. J Immunol (2009) 182:3202-12. doi:10.4049/jimmunol.0802722.
9. Fu X, Zunich SM, O'Connor JC, Kavelaars A, Dantzer R, Kelley KW. Central administration of lipopolysaccharide induces depressive-like behavior in vivo and activates brain indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures. J Neuroinflammation (2010) 7:1-12. doi:10.1186/1742-2094-7-43.
10. O'Connor JC, André C, Wang Y, Lawson MA, Szegedi SS, Lestage J, et al. Interferon-γ and tumor necrosis factor-a mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to Bacillus Calmette-Guérin. J Neurosci (2009) 29:4200-9. doi:10.1523/JNEUROSCI.5032-08.2009.
11. André C, Connor JCO, Kelley KW, Lestage J, Dantzer R, Castanon N. Spatio-temporal differences in the profile of murine brain expression of proinflammatory cytokines and indoleamine 2,3-dioxygenase in response to peripheral lipopolysaccharide administration. J Neuroinflammation (2008) 200:90-9. doi:10.1016/j.jneuroim.2008.06.011.
12. Moreau M, Andre C, O'Connor JC, Dumich SA, Woods JA, Kelley KW, et al. Inoculation of Bacillus Calmette-Guerin to mice induces an acute episode of sickness behavior followed by chronic depressive-like behavior. Brain Behav Immun (2008) 22:1087-95. doi:10.1016/j.bbi.2008.04.001.
13. Browne CA, O'Brien FE, Connor TJ, Dinan TG, Cryan JF. Differential lipopolysaccharide-induced immune alterations in the hippocampus of two mouse strains: effects of stress. Neuroscience (2012) 225:237-48. doi:10.1016/j.neuroscience.2012.08.031.
14. Park S-E, Dantzer R, Kelley KW, McCusker RH. Central administration of insulin-like growth factor-I decreases depressive-like behavior and brain cytokine expression in mice. J Neuroinflammation (2011) 8:1-14. doi:10.1186/1742-2094-8-12.
15. Larrea E, Riezu-Boj JI, Gil-Guerrero L, Casares N, Aldabe R, Sarobe P, et al. Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol (2007) 81:3662-6. doi:10.1128/JVI.02248-06.
16. Lawson MA, Parrott JM, McCusker RH, Dantzer R, Kelley KW, O'Connor JC. Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2,3-dioxygenase-dependent depression-like behaviors. J Neuroinflammation (2013) 10:1-9. doi:10.1186/1742-2094-10-87.
17. Salazar A, Gonzalez-Rivera BL, Redus L, Parrott JM, O'Connor JC. Indoleamine 2,3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge. Horm Behav (2012) 62:202-9. doi:10.1016/j.yhbeh.2012.03.010.
18. Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. FEBS J (2012) 279:1356-65. doi:10.1111/j.1742-4658.2012.08485.x.
19. Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther (2002) 303:1-10. doi:10.1124/jpet.102.034439.
20. Young KD, Drevets WC, Dantzer R, Teague TK, Bodurka J, Savitz J. Kynurenine pathway metabolites are associated with hippocampal activity during autobiographical memory recall in patients with depression. Brain Behav Immun (2016) 56:335-42. doi:10.1016/j.bbi.2016.04.007.
21. Parikh NU, Aalinkeel R, Reynolds JL, Nair BB, Sykes DE, Mammen MJ, et al. Galectin-1 suppresses methamphetamine induced neuroinflammation in human brain microvascular endothelial cells: neuroprotective role in maintaining blood brain barrier integrity. Brain Res (2015) 1624:175-87. doi:10.1016/j.brainres.2015.07.033.
22. Starossom SC, Mascanfroni ID, Imitola J, Cao L, Raddassi K, Hernandez SF, et al. Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity (2012) 37:249-63. doi:10.1016/j.immuni.2012.05.023.
23. Lekishvili T, Hesketh S, Brazier MW, Brown DR. Mouse galectin-1 inhibits the toxicity of glutamate by modifying NR1 NMDA receptor expression. Eur J Neurosci (2006) 24:3017-25. doi:10.1111/j.1460-9568.2006.05207.x.
24. Steelman AJ, Li J. Astrocyte galectin-9 potentiates microglial TNF secretion. J Neuroinflammation (2014) 11:1-12. doi:10.1186/s12974-014-0144-0.
25. Steelman AJ, Smith R, Welsh CJ, Li J. Galectin-9 protein is up-regulated in astrocytes by tumor necrosis factor and promotes encephalitogenic T-cell apoptosis. J Biol Chem (2013) 288:23776-87. doi:10.1074/jbc. M113.451658.
26. Jeon S-B, Yoon HJ, Chang CY, Koh HS, Jeon S-H, Park EJ. Galectin-3 exerts cytokine-like regulatory actions through the JAK-STAT pathway. J Immunol (2010) 185:7037-46. doi:10.4049/jimmunol.1000154.
27. Liu FT, Rabinovich GA. Galectins: regulators of acute and chronic inflammation. Ann N Y Acad Sci (2010) 1183:158-82. doi:10.1111/j.1749-6632.2009.05131.x.
28. Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science (2007) 318:1141-3. doi:10.1126/science.1148536.
29. Matsumoto R, Matsumoto H, Seki M, Hata M, Asano Y, Kanegasaki S, et al. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem (1998) 273:16976-84. doi:10.1074/jbc.273.27.16976.
30. Gleason MK, Lenvik TR, McCullar V, Felices M, O'Brien MS, Cooley SA, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood (2012) 119:3064-72. doi:10.1182/blood-2011-06-360321.
31. Su EW, Bi S, Kane LP. Galectin-9 regulates T helper cell function independently of Tim-3. Glycobiology (2011) 21:1258-65. doi:10.1093/glycob/cwq214.
32. Burman J, Svenningsson A. Cerebrospinal fluid concentration of galectin-9 is increased in secondary progressive multiple sclerosis. J Neuroimmunol (2016) 292:40-4. doi:10.1016/j.jneuroim.2016.01.008.
33. Stancic M, van Horssen J, Thijssen VL, Gabius H-J, van der Valk P, Hoekstra D, et al. Increased expression of distinct galectins in multiple sclerosis lesions. Neuropathol Appl Neurobiol (2011) 37:654-71. doi:10.1111/j.1365-2990.2011.01184.x.
34. Mancuso R, Hernis A, Agostini S, Rovaris M, Caputo D, Fuchs D, et al. Indoleamine 2,3 dioxygenase (IDO) expression and activity in relapsing-remitting multiple sclerosis. PLoS One (2015) 10(6):e0130715. doi:10.1371/journal.pone.0130715.
35. Sharma R, Di Dalmazi G, Caturegli P. Exacerbation of autoimmune thyroiditis by CTLA-4 blockade: a role for IFNγ-induced indoleamine 2, 3-dioxygenase. Thyroid (2016) 26(8):1117-24. doi:10.1089/thy.2016.0092.
36. Leskela S, Serrano A, De La Fuente H, Rodriguez-Munoz A, Ramos-Levi A, Sampedro-Nunez M, et al. Graves' disease is associated with a defective expression of the immune regulatory molecule galectin-9 in antigen-presenting dendritic cells. PLoS One (2015) 10:e0123938. doi:10.1371/journal.pone.0123938.
37. Lee J, Oh J-M, Hwang JW, Ahn JK, Bae E-K, Won J, et al. Expression of human TIM-3 and its correlation with disease activity in rheumatoid arthritis. Scand J Rheumatol (2011) 40:334-40. doi:10.3109/03009742.2010.547871.
38. Trabanelli S, Ocadlíková D, Ciciarello M, Salvestrini V, Lecciso M, Jandus C, et al. The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. J Immunol (2014) 192:1231-40. doi:10.4049/jimmunol.1300720.
39. Brooks AK, Lawson MA, Smith RA, Janda TM, Kelley KW, McCusker RH. Interactions between inflammatory mediators and corticosteroids regulate transcription of genes within the kynurenine pathway in the mouse hippocampus. J Neuroinflammation (2016) 13:1-16. doi:10.1186/s12974-016-0563-1.
40. Park S-E, Lawson M, Dantzer R, Kelley KW, McCusker RH. Insulin-like growth factor-I peptides act centrally to decrease depression-like behavior of mice treated intraperitoneally with lipopolysaccharide. J Neuroinflammation (2011) 8:1-16. doi:10.1186/1742-2094-8-179.
41. Gibb J, Hayley S, Poulter MO, Anisman H. Effects of stressors and immune activating agents on peripheral and central cytokines in mouse strains that differ in stressor responsivity. Brain Behav Immun (2011) 25:468-82. doi:10.1016/j.bbi.2010.11.008.
42. Lynch MA. The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer's disease. Immunology (2013) 141:292-301. doi:10.1111/imm.12156.
43. Braidy N, Guillemin GJ, Grant R. Effects of kynurenine pathway inhibition on NAD + metabolism and cell viability in human primary astrocytes and neurons. Int J Tryptophan Res (2011) 4:29-37. doi:10.4137/IJTR.S7052.
44. Wolowczuk I, Verwaerde C, Viltart O, Delanoye A, Delacre M, Pot B, et al. Feeding our immune system: impact on metabolism. Clin Dev Immunol (2008) 2008:1-19. doi:10.1155/2008/639803.
45. Larkin PB, Sathyasaikumar KV, Notarangelo FM, Funakoshi H, Nakamura T, Schwarcz R, et al. Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice. Biochim Biophys Acta (2016) 1860(11 Pt A):2345-54. doi:10.1016/j.bbagen.2016.07.002.
46. Lawson MA, Dostal CR, Brooks AK, McCusker RH. The kynurenine pathway and neuroinflammation: the confused brain. In: Opp MR, editor. Primer of PsychoNeuroImmunology Research. Los Angeles, CA: PsychoNeuroImmunology Research Society (2016). p. 95-101.
47. Castegna A, Palmieri L, Spera I, Porcelli V, Palmieri F, Fabis-Pedrini MJ, et al. Oxidative stress and reduced glutamine synthetase activity in the absence of inflammation in the cortex of mice with experimental allergic encephalomyelitis. Neuroscience (2011) 185:97-105. doi:10.1016/j.neuroscience.2011.04.041.
48. Penberthy WT, Tsunoda I. The importance of NAD in multiple sclerosis. Curr Pharm Des (2009) 15:64-99. doi:10.2174/138161209787185751.
49. Müller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry (2007) 12:988-1000. doi:10.1038/sj.mp.4002006.
50. Metz R, Smith C, DuHadaway JB, Chandler P, Baban B, Merlo LMF, et al. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. Int Immunol (2014) 26:357-67. doi:10.1093/intimm/dxt073.
51. John S, Mishra R. Galectin-9: from cell biology to complex disease dynamics. J Biosci (2016) 41:507-34. doi:10.1007/s12038-016-9616-y.
52. Merlo LMF, Pigott E, DuHadaway JB, Grabler S, Metz R, Prendergast GC, et al. IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis. J Immunol (2014) 192:2082-90. doi:10.4049/jimmunol.1303012.
53. Wiersma VR, de Bruyn M, Helfrich W, Bremer E. Therapeutic potential of galectin-9 in human disease. Med Res Rev (2013) 33:E102-26. doi:10.1002/med.20249.
54. Merani S, Chen W, Elahi S. The bitter side of sweet: the role of galectin-9 in immunopathogenesis of viral infections. Rev Med Virol (2015) 25:175-86. doi:10.1002/rmv.1832.
55. Van Baren N, Van den Eynde BJ. Tumoral immune resistance mediated by enzymes that degrade tryptophan. Cancer Immunol Res (2015) 3(9):978-85. doi:10.1158/2326-6066.CIR-15-0095.
56. Murakami Y, Hoshi M, Imamura Y, Arioka Y, Yamamoto Y, Saito K. Remarkable role of indoleamine 2,3-dioxygenase and tryptophan metabolites in infectious diseases: potential role in macrophage-mediated inflammatory diseases. Mediators Inflamm (2013) 2013:391984. doi:10.1155/2013/391984.
57. Kanai M, Nakamura T, Funakoshi H. Identification and characterization of novel variants of the tryptophan 2,3-dioxygenase gene: differential regulation in the mouse nervous system during development. Neurosci Res (2009) 64:111-7. doi:10.1016/j.neures.2009.02.004.
58. Ott M, Litzenburger UM, Rauschenbach KJ, Bunse L, Ochs K, Sahm F, et al. Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. Glia (2015) 63:78-90. doi:10.1002/glia.22734.
59. Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis (2004) 15:618-29. doi:10.1016/j.nbd.2003.12.015.
60. Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res (2006) 1073-1074:25-37. doi:10.1016/j.brainres.2005.12.056.
61. Funakoshi H, Kanai M, Nakamura T. Modulation of tryptophan metabolism, promotion of neurogenesis and alteration of anxiety-related behavior in tryptophan 2,3-dioxygenase-deficient mice. Int J Tryptophan Res (2011) 4:7-18. doi:10.4137/IJTR.S5783.
62. Kanai M, Funakoshi H, Takahashi H, Hayakawa T, Mizuno S, Matsumoto K, et al. Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol Brain (2009) 2:1-16. doi:10.1186/1756-6606-2-8.
63. Maes M, Scharpé S, Meltzer HY, Okayli G, Bosmans E, D'Hondt P, et al. Increased neopterin and interferon-gamma secretion and lower availability of l-tryptophan in major depression: further evidence for an immune response. Psychiatry Res (1994) 54:143-60. doi:10.1016/0165-1781(94)90003-5.